Insite Vision to Hold 2004 Fourth Quarter and Year End Financial Resul

    Business Editors/Health/Medical Writers

    ALAMEDA, Calif.--(BUSINESS WIRE)--March 28, 2005--InSite Vision Incorporated (AMEX:ISV) - an ophthalmic therapeutics, diagnostics and drug-delivery company - today announced that the Company will release 2004 fourth quarter and year end financial results before market open on Thursday, March 31, 2005. S. Kumar Chandrasekaran, Ph.D., chief executive officer and Sandra Heine, vice president, finance and administration, will host an investment-community conference call beginning at 10:30 a.m. Eastern Time on Thursday, March 31, 2005 to discuss these results and to answer questions.
    Individuals interested in listening to the conference call may do so by dialing (888) 803-7364 for domestic callers or (706) 634-1033 for international callers. A telephone replay will be available for 48 hours following the conclusion of the call by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international), and entering reservation code 5013428.
    The live conference call will also be available via the Internet on the investor relations section of the Company's Web site at www.insitevision.com, and a recording of the call will be available for 90 days following the completion of the call.

    About InSite Vision

    InSite Vision is an ophthalmic company focused on ocular infections, glaucoma and retinal diseases. The Company's lead product is AzaSite(TM), which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's patented drug-delivery vehicle, which offers the benefit of a low-dosing regimen, attractive to both the eye-care patient and physician. Pending the results of Phase 3 clinical testing currently underway and filing and approval of a New Drug Application with the Food and Drug Administration, the Company currently expects to commercially launch AzaSite in the United States in 2006, while seeking to expand this "technology platform" to include additional indications and product options for the worldwide market.
    In the glaucoma area, the Company has continued to focus genomic research on the TIGR gene, among other genes in its genomic portfolio. A portion of this research has been incorporated into the Company's commercially available OcuGene(R) glaucoma genetic test for disease management, which is a prognostic tool designed to detect a genetic marker (mt-1) in the promoter region of the glaucoma-related TIGR gene. Additional information can be found at www.insitevision.com.

    This press release, conference call and the webcast may contain, among other things, certain statements of a forward-looking nature relating to future events or the future business performance of InSite Vision, such as the timing of initiation and completion of current and future clinical trials, the success thereof, the potential benefits and commercialization of AzaSite, and the timing and success thereof. Such statements entail a number of risks and uncertainties, including but not limited to: InSite Vision's ability to enroll and complete future clinical trials for AzaSite; the results of InSite Vision's clinical trials, particularly for AzaSite; InSite Vision's ability to commence, complete and file an NDA with the U.S. FDA for AzaSite and its other product candidates, and receive approval from the FDA for the commercialization of AzaSite and its other product candidates; InSite Vision's ability to expand its technology platform to include additional indications and patent options; InSite Vision's ability to obtain additional financing when needed; the effects of its expense control activities on its operations and product development; its ability to obtain regulatory approval and market acceptance of its products and product candidates, including its OcuGene glaucoma genetic test, AzaSite, ISV-205 and ISV-014; InSite Vision's ability to maintain and develop additional collaborations and commercial agreements with corporate partners, including those with respect to AzaSite and ISV-205; its reliance on third parties for the development, marketing and sale of its products; the initiation and results of preclinical and clinical studies; its ability to adequately protect its intellectual property; and determinations by the FDA, including those with respect to OcuGene, AzaSite and ISV-205. Reference is made to the discussion of risk factors detailed in InSite Vision's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the 2003 fiscal year, as amended, and its quarterly reports on Form 10-Q. Any projections in this press release and/or conference call are based on the limited information currently available to InSite Vision, which is subject to change. Although any such projections and the factors influencing them will likely change, InSite Vision undertakes no obligation to update the information. Such information speaks only as of the date of its release. Actual events or results could differ materially and one should not assume that the information provided in this release and/or conference call is still valid at any later date.

    Note to Editors: OcuGene is written with a "small cap" G; if doing so is not possible, please use an upper case G. InSite Vision Incorporated, InSite Vision, DuraSite and OcuGene are trademarks of InSite Vision Incorporated. Other trademarks that may be mentioned in this release are the intellectual property of their respective owners.

--30--SM/la*

CONTACT: InSite Vision Incorporated S. Kumar Chandrasekaran or Sandra Heine, 510-865-8800 www.insitevision.com or Investor Contacts: Lippert/Heilshorn & Associates, Inc. Bruce Voss (bvoss@lhai.com) Jody Cain (jcain@lhai.com) 310-691-7100 www.lhai.com or Media Contacts: Lippert/Heilshorn & Associates, Inc. Chenoa Taitt (ctaitt@lhai.com) Michael Hopkins (mhopkins@lhai.com) 212-838-3777 www.lhai.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY CONFERENCE CALLS SOURCE: InSite Vision Incorporated

Copyright Business Wire 2005